Table 1 Patient and treatment characteristics for different dose groups
From: Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study
Factor | Level | SaRT | SbRT | ScRT | P value |
|---|---|---|---|---|---|
N | 259 | 163 | 180 | ||
Gender | Female | 38 (14.7%) | 23 (14.1%) | 24 (13.3%) | 0.92 |
Male | 221 (85.3%) | 140 (85.9%) | 156 (86.7%) | ||
Age, median (IQR) | 54 (45, 64) | 55 (45, 63) | 51 (44, 58.5) | 0.030 | |
Age ≥ 60 | No | 164 (63.3%) | 105 (64.4%) | 137 (76.1%) | 0.012 |
Yes | 95 (36.7%) | 58 (35.6%) | 43 (23.9%) | ||
HBV | Positive | 188 (72.6%) | 115 (70.6%) | 123 (68.3%) | 0.17 |
Negative | 33 (12.7%) | 25 (15.3%) | 38 (21.1%) | ||
Unknown | 38 (14.7%) | 23 (14.1%) | 19 (10.6%) | ||
AFP status | 0–8 | 80 (30.9%) | 38 (23.3%) | 35 (19.4%) | < 0.001 |
8–200 | 95 (36.7%) | 40 (24.5%) | 41 (22.8%) | ||
200–400 | 16 (6.2%) | 8 (4.9%) | 11 (6.1%) | ||
> 400 | 56 (21.6%) | 68 (41.7%) | 86 (47.8%) | ||
Unknown | 12 (4.6%) | 9 (5.5%) | 7 (3.9%) | ||
PT, median (IQR) | 13.3 (12.7, 14.3) | 13.4 (12.6, 14.2) | 13.15 (12.5, 14.25) | 0.58 | |
INR, median (IQR) | 1.11 (1.05, 1.2) | 1.12 (1.05, 1.2) | 1.1 (1.045, 1.215) | 0.86 | |
Tbil, median (IQR) | 13.7 (9.6, 19.5) | 14 (10, 21.5) | 14.1 (9.85, 20.75) | 0.58 | |
Dbil, median (IQR) | 5.3 (3.7, 8.7) | 6.3 (4.1, 10.7) | 6.4 (4.5, 10.45) | 0.012 | |
albumin, median (IQR) | 38 (34.2, 41.7) | 36.9 (33.5, 40.1) | 35.95 (31.8, 39.4) | < 0.001 | |
AST, median (IQR) | 32 (23, 48) | 37 (25, 55) | 41.5 (26, 59.5) | 0.005 | |
ALT, median (IQR) | 31 (21, 43) | 31 (20, 46) | 32.5 (23.5, 49.5) | 0.31 | |
ALP, median (IQR) | 86 (67, 120) | 101 (78, 142) | 111 (87.5, 151.5) | < 0.001 | |
ALBI score, median (IQR) | − 2.52 (− 2.83, − 2.10) | − 2.38 (− 2.70, − 2.04) | − 2.28 (− 2.62, − 1.93) | < 0.001 | |
ALBI grade | 1 | 113 (43.6%) | 59 (36.2%) | 47 (26.1%) | 0.002 |
2 | 137 (52.9%) | 92 (56.4%) | 123 (68.3%) | ||
3 | 9 (3.5%) | 12 (7.4%) | 10 (5.6%) | ||
CTP class | A | 212 (81.9%) | 131 (80.4%) | 139 (77.2%) | 0.63 |
B | 45 (17.4%) | 30 (18.4%) | 37 (20.6%) | ||
C | 2 (0.8%) | 2 (1.2%) | 4 (2.2%) | ||
TD ≥ 42 Gy | No | 13 (5.0%) | 69 (42.3%) | 73 (40.6%) | < 0.001 |
Yes | 246 (95.0%) | 94 (57.7%) | 107 (59.4%) | ||
Fractions | 1 | 6 (2.3%) | 0 (0.0%) | 0 (0.0%) | < 0.001 |
2 | 6 (2.3%) | 1 (0.6%) | 0 (0.0%) | ||
3 | 230 (88.8%) | 68 (41.7%) | 44 (24.4%) | ||
4 | 11 (4.2%) | 86 (52.8%) | 85 (47.2%) | ||
5 | 6 (2.3%) | 7 (4.3%) | 47 (26.1%) | ||
6 | 0 (0.0%) | 1 (0.6%) | 4 (2.2%) | ||
Per dose, median (IQR) | 15 (14, 15) | 11.5 (11.125, 13) | 10.5 (9, 10.625) | < 0.001 | |
Recurrence/residual disease | No | 137 (52.9%) | 83 (50.9%) | 72 (40.0%) | 0.022 |
Yes | 122 (47.1%) | 80 (49.1%) | 108 (60.0%) | ||
BCLC stage | A | 139 (53.7%) | 45 (27.6%) | 30 (16.7%) | < 0.001 |
B | 57 (22.0%) | 42 (25.8%) | 39 (21.7%) | ||
C | 60 (23.2%) | 74 (45.4%) | 107 (59.4%) | ||
D | 3 (1.2%) | 2 (1.2%) | 4 (2.2%) | ||
Tumor size, median (IQR) | 3.7 (2.5, 6) | 6 (4, 9.4) | 8.1 (5.45, 11) | < 0.001 |